Highly effective antibodies
Recombinant monoclonal antibodies with very high biological and therapeutic efficacy are being developed and produced on the EMABling® technology platform.
These antibodies have an optimized fucosylation profile, allowing them to bind more effectively to effector cells. The technology used for EMABling® provides an improvement of the cytotoxic and phagocytic activity to the monoclonal antibodies, in addition to their high degree of specificity for target cells.This technology is covered by several patents filed worldwide
Production on the Alès site
The monoclonal antibodies produced on EMABling® are manufactured by LFB BIOMANUFACTURING using cell culture and offered for on-site services, in the Alès plant in France.